drugset / Trial / NCT01829802
RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this pilot study is to assess the efficacy and safety of the combination of RAL+ATV/r in comparison with TDF/FTC+ATV/r in HIV-1 infected patients presenting virologic failure and PI and TDF naïve.
Timeline
- Start
- 2014-05
- Primary completion
- 2017-10
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Raltegravir | Other / unclassified | 400 mg | — |
| Comparator | Tenofovir | Small molecule | 300 mg | — |
| Comparator | emtricitabine | Other / unclassified | 200 mg | — |
| Background | Atazanavir | Other / unclassified | 300 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |